HCT Consolidation Improves Survival in Younger MCL Patients

News
Video
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

This video highlights results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant during first remission.

In this video, Brian T. Hill, MD, PhD, of the Cleveland Clinic in Ohio, discusses results of a retrospective review that examined survival and other outcomes in younger mantle cell lymphoma (MCL) patients who received consolidation with autologous hematopoietic cell transplant (HCT) during first remission.

Results of the study (abstract 341) were presented last week at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
5 experts in this video
5 experts in this video
Related Content
The FDA originally placed a clinical hold on the program for tab-cel in January 2025 due to Good Manufacturing Practice (GMP) compliance issues associated with a pre-license inspection of a third-party manufacturing facility.

FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease

Russ Conroy
May 7th 2025
Article

Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related post-transplant lymphoproliferative disease.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera

Tim Cortese
May 6th 2025
Article

The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Large B-Cell Lymphoma

Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Large B-Cell Lymphoma

American Society for Transplantation and Cellular Therapy
April 24th 2025
Article

In a multicenter retrospective study authors examined the impact of prior inotuzumab ozogamicin exposure on the outcomes of brexu-cel therapy in adults with R/R B-cell ALL.